The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and ...

GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 /uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...

Lentiviral vectors are one of the foundational technologies of cell and gene therapy. Along with adenoviral vectors, they are one of the most widely used means of introducing genetic information into ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

Lentiviral Vector CDMO Market Overview: The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell ...

Lentiviral vectors effectively deliver the gene that encodes coagulation factor IX (FIX) to the liver in dogs with naturally occurring hemophilia B (factor IX deficiency), researchers report in an ...

Engineered for exceptional lentiviral productivity, the 293TH line consistently delivers high titers, producing up to five times higher transduction titers than traditional adherent 293T cells. Fully ...